Corcept Therapeutics Inc

Following activation of a Bearish Pivot Point and break below the 9- and 20-day EMAs, CORT exhibits a medium-term bearish bias under a Stage 4 decline. Short-term price shows rejection at these EMAs and the 50-day SMA acting as resistance, with no signs of stabilization or exhaustion. Immediate sell-side engagement into this resistance zone is advised, while a sustained close above the EMAs would invalidate the downside bias.

• ↑Q2 2026 revenue +32% YoY to $256.1M; raised 2025 guidance to $800M–$850M
• ↑Korlym sales and LIFYORLI launch boost prescriptions +42.5% YoY
• ↓Net income plunged to $19.7M from $47.2M YoY amid higher expenses